Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pasteur Sanofi/Centocor

This article was originally published in The Gray Sheet

Executive Summary

Ink non-exclusive worldwide distribution pact in the cancer field. Under the terms of the deal, Pasteur Sanofi Diagnostics will distribute, in conjunction with its own Access automated instrument, five tumor markers developed by Centocor: CA 19-9, CA 125, CA 15-3, CA 72-4, and PSA. The markers add to the CEA and alpha-fetoprotein tumor markers previously developed by Daiichi Pure Chemicals, Pasteur Sanofi Diagnostics' partner and exclusive distributor in Japan. Sanofi began marketing the Access in mid- 1993. The analyzer is available with 15 assays worldwide and 13 in the U.S
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel